From Investing.com: 2024-11-19 03:31:00

Bayer partners with Cytokinetics to acquire rights in Japan for experimental heart drug aficamten. Cytokinetics to receive 50 million euros upfront, with potential for additional 90 million euros based on development achievements. Deal includes up to 490 million euros in sales milestones for hypertrophic cardiomyopathy treatment. Bayer aims to strengthen cardiovascular business amid financial challenges. Also acquired heart drug acoramidis rights in Europe for up to $310 million.



Read more at Investing.com: Bayer acquires rights to Cytokinetics’ heart drug in Japan By Reuters